Results 41 to 50 of about 47,221 (287)

Redefining the role of anthracyclines in early breast cancer treatment

Academia Oncology
Anthracyclines have long been a cornerstone of early breast cancer treatment, contributing to significant reductions in recurrence and improvements in survival.
Guilherme Nader-Marta, Martine Piccart
doaj   +1 more source

MODERN VIEW ON CARDIOTOXICITY OF CHEMOTHERAPEUTICS IN ONCOLOGY INCLUDING ANTHRACYCLINES

Российский кардиологический журнал, 2017
High efficacy of contemporary chemical and radiation treatments made it to success in treatment of oncohematological diseases. The fundamentals of many schemes of polychemotherapy of the first line are anthracyclines.
G. E. Gendlin, E. I. Emelina, I. G. Nikitin, Yu. A. Vasyuk   +3 more
doaj   +1 more source

HER2 testing in breast cancer: Opportunities and challenges [PDF]

, 2006
Human epidermal growth factor receptor 2 (HER2) is overexpressed in 15-25% of breast cancers, usually as a result of HER2 gene amplification. Positive HER2 status is considered to be an adverse prognostic factor. Recognition of the role of HER2 in breast
Annette Lebeau, Arnould L, Baselga J, Bast, Bilous M, Carter P, Cho HS, Clynes RA, Cobleigh MA, Connor CS, Crowder RJ, Dandachi N, De Laurentiis M, Di Leo A, Di Loreto C, Goldhirsch A, Gschwind A, Hancock MC, Hanna W, Harari D, Hortobagyi GN, Hudziak RM, Jacobs TW, Kobayashi M, Lebeau A, Lohrisch C, Mass R, Mass R, Molina MA, Mueller-Holzner E, Nagata Y, Osborne CK, Paik S, Piccart MJ, Piccart-Gebhart MJ, Pietras RJ, Pinto AE, Revillion F, Romond EP, Ross JS, Seidman AD, Sliwkowski MX, Tanner M, Taucher S, Yakes FM, Yarden Y   +45 more
core   +1 more source

Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer

Molecular Oncology, EarlyView.
Dysregulation of the Hippo pathway drives nuclear accumulation of YAP/TAZ, activating stemness‐related transcriptional programs that sustain breast cancer stemness and fuel therapeutic resistance across subtypes, underscoring Hippo signaling as a targetable vulnerability. Figure created and edited with BioRender.com.
Giulia Schiavoni, Antonella Palmese, Stefano Scalera, Laura Cipriani, Davide Mascolo, Patrizia Vici, Teresa Arcuri, Lorena Filomeno, Eriseld Krasniqi, Giovanni Blandino, Giulia Bon, Marcello Maugeri‐Saccà   +11 more
wiley   +1 more source

Sensitive Analysis of Idarubicin in Human Urine and Plasma by Liquid Chromatography with Fluorescence Detection: An Application in Drug Monitoring

Molecules, 2020
A new approach for the sensitive, robust and rapid determination of idarubicin (IDA) in human plasma and urine samples based on liquid chromatography with fluorescence detection (LC-FL) was developed.
Olga Maliszewska, Natalia Treder, IIona Olędzka, Piotr Kowalski, Natalia Miękus, Tomasz Bączek, Wojciech Rodzaj, Ewa Bień, Małgorzata Anna Krawczyk, Alina Plenis   +9 more
doaj   +1 more source

Molecular mechanisms of anthracycline induced cardiotoxicity: Zebrafish come into play

Frontiers in Cardiovascular Medicine, 2023
Anthracyclines are among the most potent chemotherapeutics; however, cardiotoxicity significantly restricts their use. Indeed, anthracycline-induced cardiotoxicity (AIC) fares among the worst types of cardiomyopathy, and may only slowly and partially ...
Maryam Moossavi, Maryam Moossavi, Xiaoguang Lu, Xiaoguang Lu, Xiaoguang Lu, Joerg Herrmann, Xiaolei Xu, Xiaolei Xu   +7 more
doaj   +1 more source

Differential expression of cancer‐related genes supports prediction of poor response to first‐line treatments in T‐ALL pediatric patients with high minimal residual disease

Molecular Oncology, EarlyView.
In the present work, we have identified a transcriptional signature based on the differential expression of six genes (BCL2&MAST4, HSH2D&LAT2, METRN&PITPNM2) that would facilitate the early detection of T‐cell acute lymphoblastic leukemia (T‐ALL) patients prone to a poor treatment response and could be implemented at diagnosis, along with other risk ...
Antonio Lahera, Laura Vela‐Martín, Pablo Fernández‐Navarro, José Luis López‐Lorenzo, Javier Cornago, Pilar Llamas, Eduardo Pérez‐Gómez, José Luis Marín‐Rubio, Manuel Fresno, Javier Santos, José Fernández‐Piqueras, María Villa‐Morales   +11 more
wiley   +1 more source

Pharmacological inhibition of the PERK pathway modulates hepatocellular carcinoma growth and immune signaling

FEBS Open Bio, EarlyView.
Pharmacological inhibition of PERK in a DEN‐induced mouse model of liver cancer does not reduce tumor burden but alters cellular stress signaling. Despite blocking PERK activity, downstream stress responses, including CHOP expression, remain active, suggesting compensatory mechanisms within the unfolded protein response that may influence tumor ...
Ada Lerma‐Clavero, Maria Kopsida, Nathalie Arendt, Hans Lennernäs, Markus Sjöblom, Femke Heindryckx   +5 more
wiley   +1 more source

Cardiotoxicity of venetoclax in patients with acute myeloid leukemia: comparison with anthracyclines

Cardio-Oncology
Venetoclax is a promising drug for patients with acute myeloid leukemia (AML) ineligible for anthracycline-based treatments. In rats, venetoclax is reported to cause myocardial injury.
Takeshi Onoue, Andrew H. Matthews, Azin Vakilpour, Yu Kang, Bénédicte Lefebvre, Amanda M. Smith, Shannon R. McCurdy, Michael G. Fradley, Joseph Carver, Jesse Chittams, Marielle Scherrer-Crosbie   +10 more
doaj   +1 more source

Potent immune-dependent anticancer effects of the non-cardiotoxic anthracycline aclarubicin

OncoImmunology
Aclarubicin (also called aclacinomycin A) is an antineoplastic from the anthracycline class that is used in China and Japan but not in Europe nor in the USA.
Giulia Cerrato, Allan Sauvat, Mahmoud Abdellatif, Guido Kroemer   +3 more
doaj   +1 more source